Disease Burden of Enteroviruses
HFMD is known as a common pediatric illness. Coxsackievirus A16 (CA16) was the first viral agent isolated from patients with HFMD [8] [9] [10] . Later CA4, CA5, CA6, CA9, and CA10 as well as Coxsackievirus B (CB) were also found as etiologic agents for HFMD [11] [12] [13] [14] [15] [16] . In the Asia Pacific region, a series of HFMD epidemics with neurological complications and severe outcomes in young children had occurred since late 1990s, which prompted the establishment of national surveillance of HFMD and/or enteroviruses in some Asian countries. Japan was the first country in Asia to establish a comprehensive EV surveillance with symptom-reporting and virus identification using molecular typing (http://idsc.nih.go.jp/idwr/ ydata/report-E.html). Table 1 show the top 5 EV serotypes isolated in Japan during [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] , and different serotypes predominated each year (http://idsc.nih.go.jp/iasr/virus/virus-e.html). While EV71 seemed to have an epidemic every 3 years, CA16 was more often the prevalent type. Infections by HEV-A can also be presented with herpangina, which can sometimes be difficult to differentiate from HFMD. Annual cases of HFMD and herpangina reported from sentinel clinics ranged between 145,000 and 352,000.
Taiwan performed both disease-reporting, systematic sampling of clinical specimens for virus isolation for the EV surveillance since 1999 [17] . Case numbers of HFMD and herpangina reported from sentinel clinics ranged between 93,000 and 140,000 annually. Table 2 [17] .
EV71 surveillance in Malaysia was through sentinel clinics and virological identification in some parts of the country since 1997, and virological identification for CA16 was added after 2000 (http://sydney.edu.au/medicine/apnet/). Virological monitoring in Sarawak indicated that EV71 epidemics occurred every 3 years in 1997, 2000, and so on, but CA16 can be detected in both epidemic and inter-epidemic periods [18] . However, the cyclical pattern was not observed in Kuala Lumpur [19] . Reports of other [20] . Major EV serotypes isolated from HFMD cases were CA16 and EV71, and CA6 was also an important etiology in 2006 (Table 3) . Overall, in 7 years, CA16 and EV71 were detected in 40% and 30% of the cases, respectively [20] . Then, in the 2008 HFMD outbreak, the largest one in the decade, nearly 30,000 cases were reported, with CA6 and EV71 being predominant strains, followed by CA10 [21] .
In Overall, it is hard to compare the absolute case numbers of HFMD reported in different countries with different case definitions, data collections, and laboratory procedures. However, EV71 and CA are frequently found to co-circulate and cause HFMD in some Asian countries. Therefore, an international network of enterovirus surveillance systems is urgently needed to understand disease burden of enteroviruses; in particular, an Asian working group could be formed under the Asia-Pacific Economic Cooperation (APEC) platform.
Clinical Spectrum and Disease Burden of EV71
According to previous clinical studies conducted in northern Taiwan, symptomatic EV71 infections can progress through four stages: HFMD/herpangina (Stage 1), CNS involvement (Stage 2), cardiopulmonary failure (Stage 3), and convalescence (Stage 4) [2] . Recent follow-up studies further demonstrated that EV71 infection could cause long-term sequelaes including neurological development and cognitive function [22] . In a prospective hospital-based case-finding study, 21% of 183 EV71 infections in children ,18 months of age developed neurological complications such as meningitis and encephalitis [23] . Based on national severe enterovirus surveillance and two cross-section serological surveys, Lu et al. estimated that 130,617 Taiwanese children aged ,3 years were infected with EV71 infections in 1998 and that 273 (0.21%) of these infected children developed neurological complications [24] .Overall, the prospective hospital-based case-finding study would overestimate the proportion of EV71 infections with neurological complications and the national surveillance data would underestimate the proportion of EV71 infections with neurological complications (Table 4) .
EV71 was first isolated in California (United States of America) in 1969. Since then, EV71 has been detected globally [2, 3, 5, 25] . (Table 5) [2, 26] . Since EV71 mortality rates are heavily affected by healthcare accessibility and standards, a more relevant clinical definition, such as CNS complication, should be also used to quantify disease burden of EV71 infections in prevalent areas.
To design clinical trials of EV71 vaccines, age-specific incidence rates of EV71 infections are required to identify target populations, estimate disease burdens, define endpoints of clinical efficacy, and calculate the sample size for efficacy trials. Taiwan has a national surveillance system for severe enterovirus infections since 1998. Age-specific incidence rates of EV71-related severe infections during the 1998 epidemic have been estimated to be 27.3, 37.1, 30.0, and 23.1 per 100,000 for children aged ,6, 6-11, 12-23, and 24-35 months, respectively, which would be too low to be selected as a suitable clinical endpoint [27] . Alternatively, EV71-related mild illness such as herpangina and HFMD could be suitable clinical endpoints. An infant prospective cohort study initiated in 2006 in northern Taiwan and a nationwide EV71 epidemic occurred in 2008-2009; the age-specific incidence rates of EV71 infection during the 2008-2009 epidemic were observed to be increased from 1.71 per 100 person-years at 0-6 months of age infants to 4.09, 5.74, and 4.97 per 100 person-years at 7-12, 13-24, and 25-36 months of age children groups, respectively. In addition, the cumulative incidence rate was 15% by 36 months of age, 39% of EV71 infections developed HFMD/herpangina, and 29% of EV71 infections were asymptomatic in young children [28] . A retrospective serosurvey also found that 37% of seropositive children reported to develop HFMD/herpangina during the 1998 nationwide epidemic in Taiwan (Table 4) [27] . Overall, development of EV71 vaccines should target children ,6 months of age, and EV71-related mild illness such as herpangina and HFMD could be used as the clinical endpoints of efficacy trials. To speed up the licensure of EV71 vaccines in young infants, a multination randomized controlled efficacy trial is necessary to prove the clinical protection in this age group. Asian countries do not have harmonized enterovirus surveillance systems at the moment, and an international network for enterovirus surveillance and clinical trials is urgently needed and could be organized under the APEC public health network.
Genetic and Antigenic Variations
Based on serum neutralization tests using hyperimmune animal antisera, EV71 is classified as a single serotype. According to analysis of VP1 sequences, however, EV71 was phylogenetically divided into three distinct genogroup: A, B, and C [1, 2] . isolates that were closely related to genotype A based on analysis of VP1 genes [29] . Reasons of the reemergence of genotype A in central China is not clear, and the full genomic sequences of the isolates should be performed to clarify the issue.
In contrast, genotype B and genotype C continued to circulate around the world after the 1970s and the 1980s, respectively. Genotypes B and C can be further divided into 5 genotypes, respectively: B1 to B5 and C1 to C5. Recently, retrospective studies show that a genotype B0 virus circulated in the Netherlands as early as 1963 and a genotype C0 virus circulated in Japan as early as 1978 [3, 25] . Among these genotypes, genotype C3 was only seen in Korea in 2000, and others were found to spread either globally or regionally (Table 6 ) [30] . In the 1970s, only genotypes B1 and B2 have been reported to play roles in HFMD epidemics in America and Europe [30] . In the 1980s, genotype B2 became the predominant genotype and this EV71 lineage continued circulating in Japan, Taiwan, the United States, the Netherlands, and Australia [30] . However, a new genotype C1 appeared and replaced the predominant genotype B2 and became the major genotype in the late 1980s and the early 1990s (Table 6) .
Since 1997, the largest wave of EV71 epidemics in the history has killed thousands of children around the Asia-Pacific region. In the first HFMD epidemic in the Asian-Pacific region, various genotypes including genotypes C1, C2, B3, and B4 were observed in Malaysia in 1997, and genotype B3 was the predominant strain in the outbreak. In 2000 and 2003, genotype B4 and genotype B5 Table 4 . Comparisons on clinical spectrum of enterovirus 71 infections in children.
Reference Lee et al. [28] (N = 28) Chang et al. [27] (N = 172) Lu et al. [24] Chang et al. [23] (N = 183) (Table 6 ) [30] . In the same period, two outbreaks in 2000 and 2006 were detected in Singapore. After the 1997 epidemic in Malaysia, only three genotypes (B3, B4, and C1) were detected from 1997 to 1999 in Singapore. Afterward, the first large outbreak caused by genotype B4 in 2000 was reported in Singapore. Genotypes B4 and C1 co-circulated after the 2000 epidemic and an intragenogroup B shift (B4 to B5) appeared and this genotype B5 replacement resulted in an outbreak in 2006 (Table 6 ) [30] .
Instead of intra-genogroup B shift, inter-genogroup shifts between B and C have been detected in Taiwan. In 1998, Taiwan observed a large HFMD outbreak with 129,106 severe cases and 78 fatal cases [31] . A genetic analysis shows that genotype C2 was the predominant strain, but approximately 10% of EV71 isolates in the same period belonged to genotype B4. [32] [33] [34] . In Vietnam, genotypes C1, C4, and C5 co-circulated and C5 was the predominant one in the HFMD outbreak in 2005 [35] . From an evolution prospective, a recent analysis of 628 EV71 VP1 sequences showed that EV71 may have emerged in the human population around 1941, and rises in genetic diversity are correlated with the onset of epidemics, driven in part by the emergence of novel EV71 genotypes [4] . However, recombination might be the likely mechanism for the emergence of new enterovirus serotypes [30] . Overall, the mechanism of the Table 6 . Distribution of EV71 genotypes throughout the world from 1997 to 2010. 
Bold indicates predominant genotype. doi:10.1371/journal.pntd.0001737.t006 genogroup shift and gene recombination is not clear and needs to be clarified using a longitudinal cohort study and full genome analysis. Does the observed genetic variations cause antigenic variations? This is an important question related to the prediction of disease outbreaks and the selection of vaccine strains. It seems that EV 71 has mutated more quickly in the last 15 years and more genotypes are now spreading globally. Kung et al. did not detect significant antigenic differences between genotypes B4 and C4 viruses using acute-phase sera from hospitalized EV71 patients [36] . A serological survey in healthy Japanese children and adults detected partial antigenic differences between genotype B5 and A viruses but not among genogroup B and C viruses that were previously circulating in Japan [37] . Using sera collected from young children with primary infection of genotype B5, two studies detected partial antigenic differences between genogroup B and C but not between viruses in the same genogroup (B5 and B4 viruses) [38, 39] . By constructing an antigenic map, however, Huang et al. detected antigenic differences between genogroups B and C and also between B5 and B4 viruses [40] . It is hard to compare different studies that employed different human sera and laboratory procedures, in particular the cell lines used in the neutralization assay. A network to harmonize laboratory procedures including standard sera and viruses is required to make the comparison possible. Moreover, the clinical and epidemiological significance of the antigenic variation requires longitudinal serological studies to clarify.
In the 1970s, a novel enterovirus causing acute hemorrhagic conjunctivitis was identified right before the identification of EV71 and named as EV70. EV70 had caused large-scale epidemics in Africa and Asia in the 1970s. Since then, only local outbreaks were reported [41] . Interestingly, EV70 and EV71 had a similar pattern in the 1970s and 1980s, but only EV71 has continuously caused large-scale epidemics in Asia-Pacific countries since 1997. It would be worthy to elucidate the evolutionary mechanisms and epidemiological patterns of EV70 and EV71.
Clinical Development of EV71 Vaccines
The success of live-attenuated and inactivated poliovirus vaccines (IPV) in preventing poliomyelitis indicates the potential for preventing EV71 by vaccination. After the Bulgaria epidemic in 1975, an inactivated EV71 whole virus vaccine candidate was produced in Moscow using the similar manufacturing process of IPV and was evaluated in Bulgaria in 1976. This EV71 vaccine candidate was well tolerated and immunogenic in children 1-4 years of age [42] . For the practical reason of having no further outbreaks of EV71, the Bulgaria vaccine candidate was not further evaluated for its clinical efficacy, and no potency assay to quantify vaccine antigens had been developed. With these backgrounds, the inactivated EV71 vaccine is the candidate being evaluated in clinical trials in China, Singapore, and Taiwan (Table 7 ) [43] . All vaccine candidates are inactivated whole virus particles, but different cell lines and virus genotypes are used in different countries (C4 in China, B in Singapore, and B4 in Taiwan). It would be important to compare productivity of different cell lines and virus strains and evaluate vaccine-induced cross-reactive neutralization antibody titers against all genogroups in naïve populations.
Other major difference in these vaccine candidates are the potency assay used for product release and quantification of vaccine antigens. At the moment, the standard reagents for potency assay of EV71 vaccines are not available. Based on experiences learned from IPV vaccine, several antigenic formats exist during production of IPV and these different antigenic formats showed various capacities for inducing neutralizing antibody responses. Therefore, under the coordination of World Health Organization (WHO), reference reagents were established based on one specific antigen and used establishing assays to ensure the consistent potency of IPV. Moreover, international collaborations on harmonization of potency assays of IPV are critical for the increasing supply of IPV produced by different manufacturers [44] . Therefore, regulatory authorities in Asian countries where EV71 vaccine development programs exist would benefit from having an international network to establish international reference reagent for use in potency assays of EV71 vaccines. N Regulatory authorities in Asian countries where EV71 vaccines development programs exist would be benefited from having an international network to establish international reference reagents for use in potency assays of EV71 vaccines.
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Conclusions EV71 is highly contagious and causes life-threatening outbreaks in children in tropical Asia. Several EV71 vaccine candidates are being evaluated in clinical trials in this region. To speed up the licensure of EV71 vaccines in epidemic countries, the following challenges should be seriously addressed. Firstly, EV71 and CA are frequently found to co-circulate and cause similar clinical symptoms, such as HFMD and herpangina. The indistinguishable clinical presentations of EV71 and CA may reduce public confidence and acceptance of EV71 vaccines. A combined polyvalent vaccine that can provide protection against EV71 and other prevalent CA are therefore desirable commercially and administratively. Secondly, infants are the target population of EV71 vaccines and it would need multi-nation randomized controlled efficacy trials to prove clinical protection in this age group and justify the licensure and usage of EV71 vaccines in children. An international network for enterovirus surveillance and clinical trials is urgently needed to help design and conduct efficacy trials in epidemic countries. Thirdly, EV71 and CA are found to recombine and tend to evolve quickly in the past 15 years. Prospective cohort studies are warranted to clarify clinical and epidemiological significances of the antigenic and genetic variations, which are critical to selection of vaccine strains. Last but not least, regulatory authorities in Asian countries where EV71 vaccine development programs exist would benefit from having an international network to establish international reference reagents (standardized cell lines, virus seed, and antisera) for use in potency assays of EV71 vaccines.
